PreserVision, Biotrue Brands Help Bausch US Consumer Health See Turnaround More Clearly
Bausch + Lomb’s PreserVision supplement sales grew 17% in Q3, driving 11% growth its US consumer health business. CEO Joseph Papa says Bausch is “making great progress and expect the internal organization design” of its planned spin-off of Bausch + Lomb to be completed in a year.
You may also be interested in...
Bausch + Lomb’s Alaway Preservative-Free antihistamine eye drops launch in US, The Bausch Health Companies division planned as spin-out also recently gained South Korean approval for its Lumify OTC redness reliever drops and has submissions under review in other countries.
“We selected Lumify based on its strong business performance in years one and two, and the success it had in growing a category through premiumization," says Nielsen’s BASES leader, Ben Macedo.
Approval of Alaway Preservative Free (ketotifen fumarate, 0.035) comes 15 months after FDA submitted a complete response letter to Bausch and the active ingredient developer, Eton Pharmaceuticals.